β-Blockers and Calcium Channel Blockers as Antiarrhythmic Drugs

Cardiac Electrophysiology: Fourth Edition

Volumn , Issue , 2004, Pages 918-931

  Singh, Bramah N ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84904148008     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B0-7216-0323-8/50103-2     Document Type: Chapter

References (53)

1. Mangrum JM, DiMarco JP Acute and chronic pharmacologic management of supraventricular arrhythmias in cardiovascular therapeutics. Cardiovascular Therapeutics: A Companion to Braunwald's Heart Disease 2000, 423-444. WB Saunders, Philadelphia. 2nd ed. E. Antman (Ed.).
2. Fratt CM, Waldo AL, Camm AJ Can antiarrhythmic drugs survive survival trials?. Am J Cardiol 1998, 81:24D-34D.
3. Singh BN Antiarrhythmic drugs: A re-orientation in the light of recent developments in the control of disorders of rhythm. Am J Cardiol 1998, 81:3D-13D.
4. f Inhibition in Cardiovascular Disease 2003, 1-134. Lippincott Williams & Wilkins, London. B.N. Singh, P.M. Vanhoutte (Eds.).
5. Singh BN Overview of trends in the control of cardiac arrhythmias: Past and future. Am J Cardiol 1999, 84(9A):3R-10R.
6. Sarma JSM, Singh N, Schoenbaum MP, et al. Circadian and power spectral changes of RR and QT intervals during treatment of patients with angina pectoris with nadolol providing evidence for differential autonomic modulation of heart rate and ventricular repolarization. Am J Cardiol 1994, 74:131-136.
7. Opie LH Pharmacologic options for treatment of ischemic heart disease. Cardiovascular Therapeutics 1996, 22-57. WB Saunders, Philadelphia. T.W. Smith (Ed.).
8. Anderson JL Beta-Blockers. Card Electrophysiol Rev 2000, 4:300-307.
9. Singh BN Morbidity and mortality in cardiovascular disease: Impact of reduced heart rate. J Cardiovasc Pharmacol Ther 2001, 6:313-331.
10. Reiter MJ, Reiffel JA Importance of beta-blockade in the therapy of serious ventricular arrhythmias. Am J Cardiol 1998, 82(4A):9I-19I.
11. Reiter MJ Antiarrhythmic impact of anti-ischemic, antifailure and other cardiovascular strategies. Cardiac Electrophysiol Rev 2000, 6:194-205.
12. Camm AJ, Yap YG What should we expect from the next generation of antiarrhythmic drugs. J Cardiovasc Electrophysiol 1998, 10:307. 205.
13. Approaches to controlling cardiac arrhythmias: focus on amiodarone, the last 15 Years. Am J Cardiol 1999, 84(9A):1R-173R.
14. Meredith IT, Broughton A, Jennings GL, Esler MD Evidence of a selective increase in cardiac sympathetic activity in patients with sustained ventricular arrhythmias. N Eng J Med 1991, 325:618-624.
15. Bristow M Antiadrenergic therapy of chronic heart failure. Circulation 2003, 107:1100-1102.
16. Tan HL, Hou CJ, Lauer MR, Sung RJ Electrophysiologic mechanisms of the long QT interval syndromes and torsade de pointes. Ann Int Med 1995, 122:701-704.
17. Wiesfeld AC, Crijns HJ, Tuininga YS, Lie KI Beta adrenergic blockade in the treatment of sustained ventricular tachycardia or ventricular fibrillation. Pacing Clin Electrophysiol 1996, 19:1026-1035.
18. Hjalmarson A Effects of beta blockade on sudden cardiac death during acute myocardial infarction and the postinfarction period. Am J Cardiol 1997, 80(9B):35J-39J.
19. Gottlieb SS, McCarter RJ, Vogel RA Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction. N Engl J Med 1998, 339:489-495.
20. Singh BN, Ahmed R Class III antiarrhythmic drugs. Curr Opin Cardiol 1994, 9:12-22.
21. Julian DG, Camm AJ, Frangin G, et al. Randomized trial of effect of amiodarone on mortality in patients with left ventricular dysfunction after recent myocardial infarction: EMIAT. Lancet 1997, 349:667-674.
22. Cairns JA, Connolly SJ, Roberts RS, et al. Randomized trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarizations: CAMIAT. Lancet 1997, 349:675-682. and the CAMIAT Investigators.
23. Boutitie F, Boissel JP, Connolly SJ, et al. Amiodarone interaction with β-blockers. Analysis of the merged EMIAT and CAMIAT databases. Circulation 1999, 99:2268-2275. and the EMIAT and CAMIAT Investigators.
24. Teerlink JR, Bassie BM Beta-adrenergic blocker mortality trials in congestive heart failure. Am J Cardiol 1999, 8:94R-102R.
25. MERIT-HEFT Study Group Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL randomized intervention trial in congestive heart failure (MERIT-HF). Lancet 1999, 353:2001-2007.
26. Packer M, Bristow MR, Cohn JN, et al. The effect of Carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 1996, 334:1349-1355. for the US Carvedilol Heart Failure Study Group.
27. CIBIS-II Investigators and Committees The cardiac insufficiency bisoprolol study II CIBIS II). Lancet 1999, 353:9-13.
28. Packer M, Coats AJ, Fowler MB, et al. The carvedilol, prospective randomized cumulative survival study group. N Engl J Med 2001, 344:1651-1658.
29. Design of the Beta-Blocker Evaluation Survival Trial (BEST) The BEST Steering Committee. Am J Cardiol 1995, 75:1220-1223.
30. Kelly RA, Smith TW The pharmacology of heart failure drugs. Cardiovascular Therapeutics 1996, 176-199. WB Saunders, Philadelphia. T.W. Smith (Ed.).
31. Pinter A, Dorian P Interactions between implantable devices and antiarrhythmic drugs. Cardiac Electrophysiol Rev 2000, 4:222-226.
32. Pacifico A, Hohnloser SH, Williams JH, et al. Prevention of implantable-defibrillator shocks with sotalol. D,L-Sotalol Implantable Cardioverter-Defibrillator Study group. N Engl J Med 1999, 340:1855-1862.
33. AVID Investigators A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. Antiarrhythmics versus impaltable defibrillators (AVID) trial. New Engl J Med 1997, 337:1576-1583.
34. Connolly SJ, Sheldon R, Robert RS, Gent M Canadan Implantable Defibrillator Study(CIDS): A randomized trial of the cardioverter defibrillator against amiodarone. Circulation 1999, 101:1297-1302.
35. Kuck KH, Cappato R, Siebels J, et al. Randomized comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from cardiac arrest: The Cardiac Arrest Study Hamburg. Circulation 2000, 102:748-754.
36. Ferguson JD, DiMarco JP Contemporary management of paroxysmal supraventricular tachycardia. Circulation 2003, 107:1096-1099.
37. Biffi M, Boriani G, Sabbatani P, et al. Malignant vasovagal syncope: A randomized trial of metoprolol and clonidine. Heart 1997, 77:268-272.
38. Iskos D, Dutton, Scheinman MM, Lurie KG Usefulness of pindolol in neurocardiogenic shock. Am J Cardiol 1998, 82:1121-1124.
39. Falk RH Control of ventricular rate in atrial fibrillation. Atrial Fibrillation 1992, 255-281. Raven Press, New York. R.H. Falk, P.J. Podrid (Eds.).
40. Singh BN, Lopez B, Sarma JSM Significance of prevention of atrial fibrilltaion occurring after cardiac surgery: A time for fundamental change in strategy?. J Cardiovasc Pharmacol Ther 1998, 3:259-268.
41. Mangano DT, Layug EL, Allace A, et al. Effect of atenolol on mortalit and cardiovascualr morbidity after non-cardiac surgery. The Multicenter Study of Perioperative Ischemia Research Group. N Engl J Med 1996, 335:1713-1720.
42. Gilmour RF, Chialvo DR, Jalife J Calcium-channel blockers. Electropharmacological Control of Cardiac Arrhythmias 1994, 255-264. Futura Publishing, Mt. Kisco, NY,. B.N. Singh, V.J. Dzau, P.M. Vanhoutte, R.L. Woosley (Eds.).
43. Hiromasa S, Coto H, Li ZY, et al. Dextrorotary isomer of sotalol. Electrophysiologic effects and interaction with verapamil. Am Heart J 1988, 116:1552-1557.
44. Frishman WH Mibefradil: A new selective T-channel calcium antagonist for hypertension and angina pectoris. J Cardiovasc Pharmacol Ther 1997, 2:321-330.
45. Singh BN Calcium-channel blockers and adenosine as antiarrhythmic drugs. Cardiovascular Pharmacology and Therapeutics 1994, 747-764. Churchill Livingstone, New York. B.N. Singh, V.J. Dzau, P.M. Vanhoutte, R.L. Woosley (Eds.).
46. Camm AJ, Garratt CJ Adenosine and supraventricular tachycardia. N Engl J Med 1991, 25:1621-1629.
47. The Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Investigators A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2000, 347:1285-1833.
48. Ellenbogen KA, Dias VC, Plumb VJ, et al. A placebo-controlled trial of continuous diltiazem infusion for 24-hour heart rate control during atrial fibrillation and atrial flutter: A multi-center study. J Am Coll Cardiol 1991, 18:891-897.
49. Heywood JT, Graham B, Marais GE, Jutzy KR Effects of intravenous diltiazem on rapid atrial fibrillation accompanied by congestive heart failure. Am J Cardiol 1991, 67:1150-1152.
50. Farshi R, Kistner D, Sarma JSM, et al. Ventricular rate control in chronic atrial fibrillation during daily activity and exercise by five pharmacological regimens. J Am Coll Cardiol 1999, 33:304-310.
51. Teo KK, Yusuf S Overview of antiarrhythmic drug trials: Implications for antiarrhythmictherapy. Cardiovascular Pharmacology and Therapeutics 1994, 631-643. Churchill Livingstone, New York. B.N. Singh, V.J. Dzau, P.M. Vanhoutte, R.L. Woosley (Eds.).
52. Wyse DG Calcum channel blockers. Card Electrophysiol Rev 2000, 4:308-311.
53. Lee SH, Chen SA, Tai CT, et al. Electropharmacologic charcateristics and radiofrequency catheter ablation of sustained ventricular tachycardia in patients in patients without structural heart disease. Cardiology 1996, 87:33-41.